Literature DB >> 7800784

Profile of HIV seropositive inmates diagnosed in Maryland's state correctional system.

N Kendig1, T Stough, P Austin, L Kummer, A Swetz, D Vlahov.   

Abstract

Correctional systems increasingly serve as the health care nexus for the initial diagnosis and treatment of human immunodeficiency virus (HIV) infection, particularly among traditionally underserved populations. A survey was conducted to describe the clinical profile of inmates in a State correctional system diagnosed with HIV infection by various testing strategies. Approximately 50 percent of the inmates diagnosed were potential candidates for anti-retroviral therapy, and 17 percent were severely immunocompromised. Implementation of voluntary HIV testing at prison entry increased the number of persons identified with HIV infection; however, since volunteers at entry had higher CD4 cell counts compared with infected inmates diagnosed by other methods, there was not a parallel increase in the percentage requiring immediate medical treatment. These data are important for planning medical resources in the correctional setting and underscore the opportunity to provide prevention and therapy for a vulnerable population with HIV infection. Public health interventions within the correctional setting have a broader societal impact, since most infected inmates serve short sentences (median, 3 years). Clinical case management is critical for inmates with HIV infection released to the community so that linkages with primary care providers and support services can be established.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7800784      PMCID: PMC1403577     

Source DB:  PubMed          Journal:  Public Health Rep        ISSN: 0033-3549            Impact factor:   2.792


  8 in total

1.  CD4 lymphocyte concentrations in patients with newly identified HIV infection attending STD clinics. Potential impact on publicly funded health care resources.

Authors:  C M Hutchinson; C Wilson; C A Reichart; V C Marsiglia; J M Zenilman; E W Hook
Journal:  JAMA       Date:  1991-07-10       Impact factor: 56.272

Review 2.  Correctional health care: a public health opportunity.

Authors:  J B Glaser; R B Greifinger
Journal:  Ann Intern Med       Date:  1993-01-15       Impact factor: 25.391

3.  Preliminary analysis of the Concorde trial. Concorde Coordinating Committee.

Authors:  J P Aboulker; A M Swart
Journal:  Lancet       Date:  1993-04-03       Impact factor: 79.321

4.  Zidovudine and the natural history of the acquired immunodeficiency syndrome.

Authors:  R D Moore; J Hidalgo; B W Sugland; R E Chaisson
Journal:  N Engl J Med       Date:  1991-05-16       Impact factor: 91.245

5.  Zidovudine in persons with asymptomatic HIV infection and CD4+ cell counts greater than 400 per cubic millimeter. The European-Australian Collaborative Group.

Authors:  D A Cooper; J M Gatell; S Kroon; N Clumeck; J Millard; F D Goebel; J N Bruun; G Stingl; R L Melville; J González-Lahoz
Journal:  N Engl J Med       Date:  1993-07-29       Impact factor: 91.245

6.  Voluntary testing for human immunodeficiency virus (HIV) in a prison population with a high prevalence of HIV.

Authors:  C Behrendt; N Kendig; C Dambita; J Horman; J Lawlor; D Vlahov
Journal:  Am J Epidemiol       Date:  1994-05-01       Impact factor: 4.897

7.  Zidovudine in asymptomatic human immunodeficiency virus infection. A controlled trial in persons with fewer than 500 CD4-positive cells per cubic millimeter. The AIDS Clinical Trials Group of the National Institute of Allergy and Infectious Diseases.

Authors:  P A Volberding; S W Lagakos; M A Koch; C Pettinelli; M W Myers; D K Booth; H H Balfour; R C Reichman; J A Bartlett; M S Hirsch
Journal:  N Engl J Med       Date:  1990-04-05       Impact factor: 91.245

8.  Prevalence of antibody to HIV-1 among entrants to US correctional facilities.

Authors:  D Vlahov; T F Brewer; K G Castro; J P Narkunas; M E Salive; J Ullrich; A Muñoz
Journal:  JAMA       Date:  1991-03-06       Impact factor: 56.272

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.